867 related articles for article (PubMed ID: 19388986)
1. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
2. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
3. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
4. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
Ganzer R; Robertson CN; Ward JF; Brown SC; Conti GN; Murat FJ; Pasticier G; Rebillard X; Thuroff S; Wieland WF; Blana A
BJU Int; 2011 Oct; 108(8 Pt 2):E196-201. PubMed ID: 21332907
[TBL] [Abstract][Full Text] [Related]
5. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology.
Pinthus JH; Farrokhyar F; Hassouna MM; Woods E; Whelan K; Shayegan B; Orovan WL
BJU Int; 2012 Oct; 110(8):1142-8. PubMed ID: 22372721
[TBL] [Abstract][Full Text] [Related]
6. High-intensity focused ultrasound therapy for clinically localized prostate cancer.
Lee HM; Hong JH; Choi HY
Prostate Cancer Prostatic Dis; 2006; 9(4):439-43. PubMed ID: 16847468
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
8. Treatment of localized prostate cancer using high-intensity focused ultrasound.
Uchida T; Ohkusa H; Nagata Y; Hyodo T; Satoh T; Irie A
BJU Int; 2006 Jan; 97(1):56-61. PubMed ID: 16336329
[TBL] [Abstract][Full Text] [Related]
9. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
Horwitz EM; Thames HD; Kuban DA; Levy LB; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Hanks GE; Zietman AL
J Urol; 2005 Mar; 173(3):797-802. PubMed ID: 15711272
[TBL] [Abstract][Full Text] [Related]
10. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
Uchida T; Illing RO; Cathcart PJ; Emberton M
BJU Int; 2006 Sep; 98(3):537-9. PubMed ID: 16925749
[TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
12. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
13. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
Challacombe BJ; Murphy DG; Zakri R; Cahill DJ
BJU Int; 2009 Jul; 104(2):200-4. PubMed ID: 19220245
[TBL] [Abstract][Full Text] [Related]
14. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.
Blana A; Walter B; Rogenhofer S; Wieland WF
Urology; 2004 Feb; 63(2):297-300. PubMed ID: 14972475
[TBL] [Abstract][Full Text] [Related]
15. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10ng/ml].
Poissonnier L; Gelet A; Chapelon JY; Bouvier R; Rouviere O; Pangaud C; Lyonnet D; Dubernard JM
Prog Urol; 2003 Feb; 13(1):60-72. PubMed ID: 12703356
[TBL] [Abstract][Full Text] [Related]
16. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.
Blana A; Murat FJ; Walter B; Thuroff S; Wieland WF; Chaussy C; Gelet A
Eur Urol; 2008 Jun; 53(6):1194-201. PubMed ID: 17997026
[TBL] [Abstract][Full Text] [Related]
17. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
18. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
19. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
20. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy.
Hayashi M; Shinmei S; Asano K
Int J Urol; 2007 Nov; 14(11):1048-50. PubMed ID: 17956536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
